OPT-302 (Sozinibercept) is an investigational medicine given as an injection into the eye, being studied for the treatment of 'wet' Age-related Macular Degeneration (AMD) in combination with other standard anti-VEGF therapies.
| Drug class | VEGF-C/D Inhibitor (Investigational) |
|---|---|
| Type | Single |
| Forms | Intravitreal Injection |
| Common strength | Per dose |
| Prescription status | Investigational |
What OPT-302 (Sozinibercept) is used for
OPT-302 (Sozinibercept) is an investigational medicine that is currently being studied for its potential use in treating a specific eye condition:
- Wet Age-related Macular Degeneration (Wet AMD): This medicine is being investigated for use in combination with standard anti-VEGF therapies for wet AMD. Wet AMD is a serious eye condition that affects the macula, the central part of your retina responsible for sharp, detailed vision. In wet AMD, abnormal blood vessels grow under the retina and leak fluid or blood, leading to blurred vision, distorted vision, or a blind spot in your central vision.
It is important to remember that OPT-302 (Sozinibercept) is not yet approved or routinely available in India. It is currently part of clinical trials to understand its effectiveness and safety.
How it works
OPT-302 (Sozinibercept) works by targeting specific proteins in your eye called VEGF-C and VEGF-D. In conditions like wet AMD, certain proteins, particularly VEGF-A, contribute to the growth of abnormal blood vessels that leak and damage vision. Standard anti-VEGF treatments primarily block VEGF-A.
OPT-302 (Sozinibercept) is designed to complement these standard treatments by blocking VEGF-C and VEGF-D. By blocking these additional proteins, it aims to further reduce the growth and leakage of abnormal blood vessels, potentially offering a more comprehensive approach when used in combination with existing anti-VEGF-A therapies for wet AMD. This combined action is hoped to provide better outcomes for patients.
How it’s used
OPT-302 (Sozinibercept) is administered as an intravitreal injection, which means it is given directly into the vitreous gel, the clear jelly-like substance that fills the centre of your eye. This procedure is performed by a retina specialist in a sterile environment to ensure safety and precision.
Since OPT-302 (Sozinibercept) is an investigational medicine, its exact dosing schedule is determined by the specific clinical trial protocol. This means the frequency and number of injections will follow strict guidelines set out for the research study. It is used as a combination therapy alongside standard anti-VEGF treatments.
Your retina specialist will explain the procedure in detail, including what to expect before, during, and after the injection. They will also advise you on any specific instructions or follow-up appointments required as part of the trial.
Always follow your ophthalmologist’s exact instructions.
Brands in India
Hospital-prepared or not marketed as a retail brand in India.
Please note
Given as an injection inside the eye by a retina specialist. After any intravitreal injection, seek help IMMEDIATELY if you develop increasing pain, redness, sensitivity to light or a drop in vision — these can be signs of a serious infection (endophthalmitis). Not currently approved or routinely available in India — included for reference; ask your ophthalmologist about approved alternatives.
Precautions & side effects
OPT-302 (Sozinibercept) is an investigational medicine used as a combination therapy. As with any intravitreal injection, there are important precautions to be aware of:
- Immediate Medical Attention Required: After receiving an intravitreal injection, it is crucial to seek medical help IMMEDIATELY if you experience any of the following symptoms: increasing pain in the eye, increased redness, increased sensitivity to light (photophobia), or a noticeable drop in your vision. These symptoms can be signs of a serious eye infection called endophthalmitis, which requires urgent treatment to prevent severe vision loss.
- Investigational Status: Please remember that OPT-302 (Sozinibercept) is currently an investigational medicine. This means it is not yet approved or routinely available for general use in India. It is being studied in clinical trials to evaluate its safety and effectiveness.
- Administered by a Specialist: This medicine is given as an injection inside the eye and must only be administered by a qualified retina specialist.
- Discussion with Your Doctor: If you have wet AMD, it is important to discuss all available and approved treatment options with your ophthalmologist. They can provide information on established alternatives that are routinely available in India.
Understanding Wet Age-related Macular Degeneration (Wet AMD)
Wet Age-related Macular Degeneration (Wet AMD) is a leading cause of severe vision loss, particularly in older adults. It affects the macula, a small but vital part of your retina located at the back of your eye. The macula is responsible for your sharp, central vision, which you use for tasks like reading, recognising faces, and driving. In wet AMD, abnormal and fragile blood vessels begin to grow under the macula. These vessels are prone to leaking fluid and blood, which can damage the light-sensitive cells of the macula. This leakage leads to symptoms such as blurred central vision, distorted vision (straight lines appearing wavy), or a dark spot in the centre of your vision. Early detection and treatment are crucial to help preserve your vision. Regular eye check-ups, especially if you are over 50 or have a family history of AMD, are highly recommended. If you notice any changes in your central vision, such as blurriness, distortion, or difficulty seeing fine details, it is important to consult an ophthalmologist promptly.
General Advice for Intravitreal Injections
Intravitreal injections are a common and effective way to deliver medicine directly to the retina for various eye conditions. While the thought of an eye injection might seem daunting, it is a routine procedure performed by skilled retina specialists. Before the injection, your eye will be numbed with anaesthetic eye drops to minimise discomfort. The area around your eye will be cleaned thoroughly to prevent infection. During the injection, you might feel a slight pressure, but typically no pain. After the injection, it is normal to experience some mild irritation, redness, or a feeling of something in your eye for a day or two. You might also see small floaters or air bubbles in your vision, which usually disappear on their own. It is vital to follow all post-injection instructions given by your doctor, which may include avoiding rubbing your eye, using prescribed eye drops, and knowing when to seek urgent medical attention. Maintaining good eye hygiene, such as washing your hands before touching your eyes, is always important.
When to Seek Urgent Medical Help
While intravitreal injections are generally safe, it is extremely important to be aware of potential complications and know when to seek immediate medical help. The most serious, though rare, complication is an eye infection called endophthalmitis. This condition requires urgent treatment to save your vision. You must contact your ophthalmologist or go to the nearest eye emergency department IMMEDIATELY if you experience any of the following symptoms after an intravitreal injection: increasing eye pain that gets worse over time, significant increase in eye redness, extreme sensitivity to light (photophobia), or a sudden and noticeable drop in your vision. These symptoms could indicate a serious infection or other complications and should never be ignored. Do not wait for your next scheduled appointment; seek help without delay. Your vision is precious, and timely action can make a significant difference in the outcome.
Frequently asked questions
What is OPT-302 (Sozinibercept) used for?
OPT-302 (Sozinibercept) is an investigational medicine being studied for the treatment of 'wet' Age-related Macular Degeneration (Wet AMD). It is intended to be used in combination with standard anti-VEGF therapies for this condition.
How does OPT-302 (Sozinibercept) work?
OPT-302 (Sozinibercept) works by blocking specific proteins called VEGF-C and VEGF-D. This action complements standard anti-VEGF-A therapies, which primarily block VEGF-A. By targeting multiple VEGF proteins, it aims to reduce the growth and leakage of abnormal blood vessels in the eye that contribute to wet AMD.
What are the common Indian brands for OPT-302 (Sozinibercept)?
OPT-302 (Sozinibercept) is currently an investigational medicine and does not have any retail brands available in India. It is not yet approved or routinely available for general use.
How is OPT-302 (Sozinibercept) administered?
OPT-302 (Sozinibercept) is given as an intravitreal injection, meaning it is injected directly into the eye. This procedure is performed by a retina specialist following a specific clinical trial protocol for dosing.
Do I need a prescription for OPT-302 (Sozinibercept)?
Yes, OPT-302 (Sozinibercept) is an investigational medicine and would require a prescription from a retina specialist if it were to become available. Currently, it is only used within clinical trial settings.
What are the key precautions to take with OPT-302 (Sozinibercept)?
Since OPT-302 (Sozinibercept) is given as an injection inside the eye, it is crucial to seek medical help IMMEDIATELY if you develop increasing pain, redness, sensitivity to light, or a drop in vision after the injection, as these can be signs of a serious infection (endophthalmitis). It is an investigational combination therapy and is not currently approved or routinely available in India.
References
- Sozinibercept (Anti-VEGF-C/-D) Combined with Ranibizumab for Polypoidal Choroidal Vasculopathy: Phase IIb Predefined Subgroup Analysis – PMC
- Diabetic Retinopathy – National Eye Institute
- Eye health – MedlinePlus (US National Library of Medicine)
- Eye health information – American Academy of Ophthalmology
- Blindness and vision impairment – World Health Organization
Medically reviewed by Dr. C Jagadesh Reddy, Chief Surgeon: Cornea, Cataract and Refractive Surgery — last reviewed 2026-07-28.
This page is for general education only and is not a substitute for professional medical advice, diagnosis or treatment. Never self-medicate or reuse an old prescription. Always consult a qualified ophthalmologist before starting, changing or stopping any eye medicine.